Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
5.90
+0.04 (0.77%)
Jun 2, 2026, 4:00 PM EDT - Market closed
Passage Bio Employees
Passage Bio had 24 employees as of December 31, 2025. The number of employees decreased by 36 or -60.00% compared to the previous year.
Employees
24
Change (1Y)
-36
Growth (1Y)
-60.00%
Revenue / Employee
n/a
Profits / Employee
-$1,569,833
Market Cap
18.91M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 24 | -36 | -60.00% |
| Dec 31, 2024 | 60 | 2 | 3.45% |
| Dec 31, 2023 | 58 | -27 | -31.76% |
| Dec 31, 2022 | 85 | -48 | -36.09% |
| Dec 31, 2021 | 133 | 59 | 79.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Curis | 24 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| NewcelX | 15 |
| Lipocine | 14 |
| AEON Biopharma | 8 |
| Exicure | 8 |
PASG News
- 14 days ago - Passage Bio Transcript: AGM 2026 - Transcripts
- 21 days ago - Passage Bio Quarterly report: Q1 2026 - Filings
- 22 days ago - Passage Bio Slides: Corporate presentation - Filings
- 6 weeks ago - Wedbush downgrades Passage Bio to Neutral on regulatory uncertainties - TheFly
- 6 weeks ago - Passage Bio downgraded to Hold from Buy at TD Cowen - TheFly
- 6 weeks ago - Passage Bio price target lowered to $15 from $30 at Oppenheimer - TheFly
- 6 weeks ago - Passage Bio downgraded to Neutral from Outperform at Wedbush - TheFly
- 6 weeks ago - Passage Bio downgraded to Neutral from Buy at Chardan - TheFly